Inflammatory Bowel Diseases

Article	Citations
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS	183
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS	76
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy	74
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease	63
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC	60
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS	58
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY	58
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD	56
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	51
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	49
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY	48
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations	48
Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission	48
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION	47
Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes	47
Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis	46
COMPARATIVE RISK OF LYMPHOMA IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH THIOPURINES AND/OR ANTI-TNF AGENTS: AN UMBRELLA REVIEW OF META-ANALYSES	44
AN INTEGRATED MULTI-OMIC APPROACH REVEALS A SHARED SIGNATURE OF IMMUNE ACTIVATION AND METABOLIC COLLAPSE IN ULCERATIVE COLITIS AND RHEUMATOID ARTHRITIS	43
Author’s Response to Comment on “Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease”	42
COMPARATIVE PERIOPERATIVE OUTCOMES OF LUMBAR SPINAL SURGERY IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	42
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study	41
Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study	41
Prior Appendectomy Is Associated With a Milder Clinical Course in Crohn’s Disease: A Nationwide Population-based Cohort Study	40
Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease	40
Wound Healing After Vaginal Delivery, Episiotomy, and Cesarean Section Delivery Among Women With IBD: Results From the PIANO Registry	40

INFLAMMATORY BOWEL DISEASE IN YOUTH UNDER 20 FROM 1990-2019: A GLOBAL PERSPECTIVE ON REGIONAL AND NATIONAL VARIATIONS FROM THE GBD 2019 ANALYSIS	40
DEVELOPMENT OF A NEXT GENERATION ENGINEERED LIVE MICROBIOME BIOTHERAPEUTIC, E COLI NISSLE 1917-TTR, FOR ULCERATIVE COLITIS	39
ROLE OF EPITHELIAL LTA4H-LTB4 SIGNALING IN RESOLUTION OF COLONIC MUCOSAL WOUNDS	38
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases	37
EVALUATING POUCH RELATED OUTCOMES WITH GLUCAGON LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS IN PATIENTS WITH ILEAL POUCH ANAL ANASTOMOSIS—A DATABASE STUDY IN THE UNITED STATES	37
EPIGENETIC REPRESSORS MAINTAIN TREG STABILITY IN A FOXP3-INDEPENDENT MANNER	37
TERTIARY LYMPHOID STRUCTURES (TLS) EXPANSION PARALLELS ILEITIS PROGRESSION IN TNFΔARE MICE, REQUIRES β7 INTEGRIN AND CCR7, AND DECREASES IN SIZE AFTER GLUCOCORTICOID ADMINISTRATION	37
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis	36
Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey	36
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED	35
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS	35
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease	35
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis	35
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients: Systematic Review With Meta-Analysis	33
Vitamin D3 andLactobacillus rhamnosusGG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation	33
The Prevalence of Chronic Opioid Use in Patients With Inflammatory Bowel Disease: A Nationwide Danish Register-Based Study Over a 25-Year Period of Time	32
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease	30
OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study	30
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN	30
AN OBSERVATIONAL STUDY DEMONSTARTING THE MEASUREMENT, CHARACTERIZATION AND VALIDATION OF EXPRESSIONS OF CALPROTECTIN IN HUMAN SWEAT THROUGH A SWEAT WEARABLE	29
INCORPORATION OF RISK ASSESSMENT TOOL IMPACTS PATIENT AND GASTROENTEROLOGIST CONFIDENCE AND TREATMENT DECISION MAKING IN BIONAIVE CROHN’S DISEASE	29
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL	29
DO PROVIDERS FAIL TO RECOGNIZE ANXIETY IN SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE?	29
EVIDENCE OF PROTEASE-MEDIATED PRO-NOCICEPTIVE EFFECTS IN INFLAMMATORY BOWEL DISEASE PATIENTS	28
Correction to: Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response	28
Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Call to Action to Improve Patient Care	28
POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON	28
Letter: Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis—Authors’ Reply	27
ASSOCIATED COST DIFFERENCES OF SWITCHING BETWEEN INFLIXIMAB PRODUCTS	27
PEDIATRIC PATIENTS WITH CORMORBID DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS AND INFLAMMATORY BOWEL DISEASE	27
Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients	27
REGIONAL AND RACIAL DISPARITIES IN ULCERATIVE COLITIS AND CHOLANGIOCARCINOMA RELATED MORTALITY IN THE UNITED STATES AND TEXAS: A 21 YEAR OBSERVATIONAL STUDY	27
SWEET AND SALTY: SWEET SYNDROME AS THE INITIAL PRESENTATION OF NEWLY DIAGNOSED ULCERATIVE COLITIS	27
Response to the Letter to the Editor: “AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps”	27
A RARE PRESENTATION OF ULCERATIVE COLITIS WITH ABSCESS FORMATION	27
TNF IS REQUIRED FOR SPONTANEOUS INNATE COLITIS IN MICE LACKING ADAPTIVE IMMUNITY	26
HUMAN β-DEFENSIN 2 ISOFORMS EXPRESSION ON PEDIATRIC IBD	26
INFECTIOUS COMPLICATIONS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	26
FREE AIR FROM WHERE? SPONTANEOUS PNEUMOMEDIASTINUM AND SUBCUTANEOUS EMPHYSEMA IN A PATIENT WITH ULCERATIVE COLITIS IN THE ABSENCE OF COLONIC OR ESOPHAGEAL PERFORATION	26
IMPACT OF PATIENT DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND SOCIAL DETERMINANTS OF HEALTH ON ADVANCED THERAPY MEDICATION ADHERENCE AND PERSISTENCE IN ULCERATIVE COLITIS ACROSS UNITED STATES PAYER TY	26
Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis	26
HIGH COPY NUMBER POLYMORPHISMS OF ALPHA DEFENSIN 1-3 ARE ASSOCIATED WITH THERAPEUTIC RESPONSIVENESS IN INFLAMMATORY BOWEL DISEASE	25
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study	25
Epidemiology of Inflammatory Bowel Disease in a Cohort of US Black Women	25
Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity	25
ULCERATIVE COLITIS-DERIVED INTESTINAL EPITHELIAL CELLS ARE PROTECTED FROM CELL DEATH BY THE IMMUNE MEDIATORS RELEASED FROM RESTING AND ACTIVATED SYSTEMIC T CELLS	25
Intestinal Ultrasound Measures are Strongly Correlated With Small Bowel Endoscopic Lewis Score in Active Crohn’s Disease	25
The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis	25
The Value of a Dedicated IBD Flare Clinic to Effectively Manage Exacerbations of Inflammatory Bowel Disease: The Edinburgh IBD Unit	25
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device	25

Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials	24
METABOLITE MIMICRY REVEALS BUTYRATE ANALOG WITH SELECTIVE PROTECTIVE FUNCTIONS IN THE INTESTINAL MUCOSA	24
Rectal and Rectosigmoid Endoscopy to Assess Endoscopic and Histological Remission in Ulcerative Colitis: A Prospective Study	24
A CASE SERIES: FEASIBILITY AND SAFETY OF ENDOSCOPIC RESECTION FOR COLORECTAL DYSPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE	24
Past But Not Forgotten: Innate Factors Affect the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease	24
Childhood Socioeconomic Characteristics and Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study	24
EFFICACY AND FEASIBILITY OF THE KOREAN CROHN’S DISEASE EXCLUSION DIET (K-CDED) IN PEDIATRIC CROHN’S DISEASE	24
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study	24
REPOGRAMING OF THE INTESTINAL IMMUNE CELL COMPARTMENT DEFINES THE RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN CROHNS DISEASE	24
The Norepinephrine-QseC Axis Aggravates F. nucleatum-associated Colitis Through Interkingdom Signaling	23
Biological Ageing and the Risk of Inflammatory Bowel Disease: Exploring the Role of Lifestyle and Genetic Susceptibility in a Nationwide Prospective Study	23
Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease	23
Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis	22
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions	22
Challenges in IBD Research 2024: Novel Technologies	22
Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn’s Disease	22
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease	22
2ʹ-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3	22
The Time to Inflammatory Bowel Disease Diagnosis for Patients Presenting with Abdominal Symptoms in Primary Care and its Association with Emergency Hospital Admissions and Surgery: A Retrospective Coh	22
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials	22
MYO5B and the Polygenic Landscape of Very Early-Onset Inflammatory Bowel Disease in an Ethnically Diverse Population	22
Potential Utility of Laser Speckle Contrast Imaging to Detect Early Microcirculatory Changes Associated With Erythema Nodosum in Crohn’s Disease: A Case Report	21
AEROMONAS IMMUNE MODULATOR PROTEINS INTERACT WITH HOST LIPOCALIN-2 TO MEDIATE INFLAMMATION THROUGH BOTH HOST- AND MICROBIOME-SPECIFIC MECHANISMS	21
THE IMPACT OF INFLAMMATORY BOWEL DISEASES ON THE OUTCOMES OF PATIENTS ADMITTED WITH ACUTE VIRAL HEPATITIS: A 2016-2019 NATIONWIDE ANALYSIS	21
EFFICACY AND SAFETY OF VEDOLIZUMAB AND TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF STEROID-REFRACTORY MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	21
The Clinical Interpretation of Cluster Trials	21
Excessive Mitochondrial Fission Suppresses Mucosal Repair by Impairing Butyrate Metabolism in Colonocytes	21
Association Between Maternal Infections in Pregnancy and the Risk of Inflammatory Bowel Disease in the Offspring: Findings From Two Scandinavian Birth Cohorts	21
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD	21
Pro-inflammatory Cytokines Promote the Occurrence and Development of Colitis-associated Colorectal Cancer by Inhibiting miR-615-5p	21
PERIPHERAL BLOOD EXTRACELLULAR VESICLE LIPIDS AS BIOMARKERS FOR HUMAN INFLAMMATORY BOWEL DISEASE	21
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria	21
IBD Journal Editorial Fellowship: A Practical Guide for Future Fellows	21
CYTOKINE MULTI-OMICS AND MACHINE LEARNING IDENTIFY MIP1ALPHA AS A NOVEL MEDIATOR IN INFLAMMATORY BOWEL DISEASE	20
CLINICAL BENEFITS OF PROBIOTIC SUPPLEMENTATION IN INFLAMMATORY BOWEL DISEASE TREATMENT: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	20
Construct Validity of the Toronto IBD Global Endoscopic Reporting Score Compared to Inflammatory Biomarkers After 12-Month Follow-Up	20
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND HIDRADENITIS SUPPURATIVA: A SINGLE-CENTER RETROSPECTIVE STUDY	20
BEYOND THE BOWEL: A CASE OF SWEET SYNDROME COMPLICATING IBD	20
EFFICACY OF UPADACITINIB INDUCTION FOR PEDIATRIC IBD	20
Comment on: “The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis”	20
Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients	20
Advancing Toward Transmural Healing in Pediatric Crohn’s Disease	20
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE	20
Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our ARM-amentarium	19
The Importance of Treatment Timing and Positioning in IBD	19
Impact of Inflammatory Bowel Disease on Patients’ Caregivers: Results From a French Survey	19
How to Minimize Placebo Response and Remission Rates	19
Aeroallergen-related Diseases Predate the Diagnosis of Inflammatory Bowel Disease	19
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Stu	19
Coronary Artery Plaque Assessment by CT Angiogram in Inflammatory Bowel Disease	19
Clinical outcomes in pregnancy after ileal pouch-anal anastomosis for ulcerative colitis	19
Genome-Wide Aggregated Trans -Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease	19
Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis	19
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib	19
Research Progress of Interleukin-27 in Inflammatory Bowel Disease	19
QUANTITATIVE SMALL BOWEL MOTILITY ASSESSMENT ON MAGNETIC RESONANCE ENTEROGRAPHY IN PEDIATRIC CROHN’S DISEASE: ASSOCIATIONS WITH CLINICAL PHENOTYPE AND SURGICAL OUTCOME	18
Distinct Effects of Autologous Hematopoietic Stem Cell Transplantation on T Cell Composition and Profile in Refractory Crohn’s Disease	18
Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis	18
Timing is Everything: Lessons Learned for Building Microbiome-Based Models in Pediatric Crohn’s Disease	18
VENOUS THROMBOEMBOLISM AND INPATIENT OUTCOMES IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM THE NATIONWIDE INPATIENT SAMPLE	18
METABOLIC INFLAMMATION IN CROHN’S DISEASE: EFFECTS OF CARNITINE PAMITOYLTRANSFERASE ACTIVITY ON INFLAMMATORY SIGNALING IN THE INTESTINAL EPITHELIUM	18
An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits	18
Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?	18
LOSS OF CGNL1 CONTRIBUTES TO VERY EARLY ONSET IBD	18
SAFETY OF PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM A LARGE ADMINISTRATIVE COHORT	18
Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis	18
Disease reprogression following surgical resection in Crohn disease	18
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series	17
Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report	17
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases	17
MICROBIAL DRIVERS OF REGION-SPECIFIC SUSCEPTIBILITY TO CHRONIC, TNF-INDUCED INTESTINAL INFLAMMATION	17
PRELIMINARY EVIDENCE FOR A RELATIONSHIP BETWEEN HEART RATE VARIABILITY AND FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)	17
IDENTIFICATION OF DISEASE SEVERITY DEFINITIONS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE	17
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease	17
Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab	17
Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis	17
REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN THE UNITED STATES OF AMERICA	17
PRIMARY EOSINOPHILIC COLITIS WITH CONCOMITANT NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE – A DIAGNOSITIC CONUNDRUM	17
Endoscopic Stenting in Crohn’s Disease-related Strictures: A Systematic Review and Meta-analysis of Outcomes	17
THE ROLE OF ALCOHOL USE IN THE DEVELOPMENT OF CROHN’S DISEASE COMPLICATIONS: A RETROSPECTIVE ANALYSIS	17

MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL U.S. COHORT	17
HISTOPATHOLOGICAL CHARACTERIZATION OF A CHRONIC DSS-INDUCED MOUSE MODEL OF IBD WITH INTESTINAL FIBROSIS	17
Reply: Plant-Based Diet Recommended for Inflammatory Bowel Disease	17
Targeting NCAPD2 as a Therapeutic Strategy for Crohn’s Disease: Implications for Autophagy and Inflammation	16
EXPLORING SYMPTOM PROFILES IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING LATENT CLASS ANALYSIS	16
ALTERATIONS IN THE MUCOSA-ASSOCIATED MICROBIOME CONTRIBUTE TO THE SEVERITY OF INFLAMMATION IN A DSS-INDUCED COLITIS MODEL	16
Enhancing the Rigor of Research on Herpes Zoster Risk in Patients with IBD Post-SARS-CoV2: Recommendations for Global and Detailed Analyses	16
Correction to: Risankizumab Is Effective for the Management of Crohn’s Disease of the Pouch	16
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS	16
INFLAMMATORY BOWEL DISEASE IN THE MEDICARE POPULATION: AN ASSESSMENT OF OUTCOMES AND RISK FACTORS IN THE APPALACHIAN REGION	16
Reply: On the Risk of Neurological Disorders in Patients With Inflammatory Bowel Disease	16
Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis	16
CONFIDENCE IN REMISSION: A KEY CONTRIBUTOR IN DEVELOPING POST-TRAUMATIC GROWTH AND MITIGATING MEDICAL TRAUMA AMONG IBD PATIENTS	16
RARE PRESENTATION OF CROHN’S DISEASE WITH ISOLATED OVARIAN INVOLVEMENT	16
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics	15
Pou2af1 Deficiency Aggravates DSS-Induced Colitis via Impaired Germinal Center Responses and Altered Gut Microbiota	15
Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study	15
The Role of Appendicectomy in Ulcerative Colitis: Systematic Review and Meta-Analysis	15
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study	15
Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis	15
Correction to: Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn’s Disease and Ulcerative Colitis—An International Meta-Analysis	15
Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Increased Infection Risk in Children of Mothers With IBD	15
QUANTITATIVE AND EXPLAINABLE ARTIFICIAL INTELLIGENCE (AI)-POWERED APPROACHES TO PREDICT ULCERATIVE COLITIS DISEASE ACTIVITY FROM HEMATOXYLIN AND EOSIN (H&E)-STAINED WHOLE SLIDE IMAGES (WSI)	15
Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation	14
Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series	14
Implementation of a Capillary Blood Self-Sampling Technique at Home for Monitoring of Patients With IBD	14
INDIGO NATURALIS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE REFRACTORY TO ADVANCED IMMUNOSUPPRESSIVE THERAPY	14
Plant-Based Diet Recommended for Inflammatory Bowel Disease	14
Perioperative anti-α4β7 Integrin Blockade Alters Wound Cell Infiltrate but Not the Functional Outcome of Ileocecal Anastomoses in Mice With Crohn’s-like Ileitis	14
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease	14
Dynamic changes in clinical response to corticosteroids in ulcerative colitis	14
Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3	14
IMPACT OF MULTI-MINERAL INTERVENTION ON THE PROTEOME OF HUMAN COLON ORGANOIDS UNDER PRO- AND ANTI-INFLAMMATORY CONDITIONS	14
IL-15 Promotes Inflammatory Th17 Cells in the Intestine	14
Single-cell Expression Atlas Reveals Cell Heterogeneity in the Creeping Fat of Crohn’s Disease	14
Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease	14
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program	14
Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact?	14
Risk Factors for Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Phase of Care	14
IBD GENETIC VARIATION CONTROLS T CELL EXPRESSION AND FUNCTION	14
Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: Supporting the Clinician’s Role in Disease Interpretation	14
Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease	14
Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study	14
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease	13
Estrogen Receptor β Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-β/Smad and TLR4/MyD88/NF-κB Signaling Pathways	13
Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn’s Disease and Ulcerative Colitis—An International Meta-Analysis	13
Management of Perianal Fistulizing Crohn’s Disease	13
ANALYSIS OF THE GENETIC EXPRESSION OF COLON CANCER GENETIC BIOMARKERS ON INFLAMMATORY BOWEL DISEASE ON BLOOD AND BIOPSY SAMPLES	13
REAL-WORLD EXPERIENCE WITH TOFACITINIB DOSE DE-ESCALATION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS	13
Deep Sequencing of Crohn’s Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression	13
Inter- and Intraobserver Variability on Endoscopic Scoring Systems in Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis	13
Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies	13
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis	13
TRENDS AND RELATED FACTORS OF QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE	13
Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort Study	13
Letter to the editor: enhancing the robustness of early vs late switch to subcutaneous infliximab in inflammatory bowel disease (IBD): the value of propensity score analysis	13
Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years	13
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials	13
IRE1α-XBP1 CONTROLS GROUP 3 INNATE LYMPHOID CELLS IN INFLAMMATORY BOWEL DISEASE	13
Dysplasia detection using high-definition scopes with dye vs virtual chromoendoscopy in IBD: A meta-analysis of randomized clinical trials	12
DETERMINING ADHERENCE TO TREAT-TO-TARGET GOALS IN INFLAMMATORY BOWEL DISEASE: INSIGHTS FROM IBD QORUS SURVEY DATA	12
STERILE NEUTROPHILIA INDUCED VIA CXCR4 ANTAGONISM MITIGATES COLONIC INFLAMMATION BY ENHANCING IMMUNOSUPPRESSIVE REGULATORY T CELLS IN MICE	12
INFLIXIMAB AND VEDOLIZUMAB HAVE SIMILAR CLINICAL AND SAFETY OUTCOMES AMONG BIOLOGIC-NAÏVE PATIENTS WITH MILD TO MODERATE PEDIATRIC INFLAMMATORY BOWEL DISEASE	12
INFLAMMATORY BOWEL DISEASES AND RISKS OF GENITOURINARY CANCERS: A SYSTEMIC REVIEW AND META-ANALYSIS	12
Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition—A Prospective Multicenter Study	12
Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update	12
BACTERIAL CROSS FEEDING: EXPLORING EFFECTS OF R. GNAVUS RELEASED MUCUS CARBOHYDRATE SUBSTRATES ON ADHERENT-INVASIVE E. COLI LF82 GROWTH AND EXPRESSION OF RELEVANT MOLECULAR PATHWAYS IN AEROBIC AND ANA	12
SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES	12
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY	12
FIBROBLAST MICROBIAL SENSING PLAYS A CRUCIAL ROLE IN MACROPHAGE-MEDIATED HOST DEFENSE AND PREDISPOSES TO IBD-RELEVANT COLITIS	12
SIMPLIFIED INDEX FOR ASSESSING MICROBIAL DIVERSITY OF THE HUMAN DIGESTIVE TRACT IN A CLINICAL SETTING	12
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review	12
BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB	12
RACIAL DISPARITIES IN CLINICAL OUTCOMES OF PATIENTS HOSPITALIZED WITH ULCERATIVE COLITIS: INSIGHTS FROM A LARGE NATIONAL DATASET	12
Reply to “Patients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccination”	12
MISSED OPPORTUNITIES FOR PREVENTING COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN AN URBAN SAFETY-NET HEALTH SYSTEM: CASE SERIES	12
Prior Authorization of Biologics in the Management of Inflammatory Bowel Disease	12
Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance	12
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease	11
Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn’s-like Disease of the Pouch	11
Shedding New Light on High-Risk Phenotypes for Pouchitis	11
In Memoriam Kim Isaacs	11
Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease	11
The Composition of the Fecal and Mucosa-adherent Microbiota Varies Based on Age and Disease Activity in Ulcerative Colitis	11
Safety and Effectiveness of QingDai ( Indigo naturalis ) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial	11
Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-	11
Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts	11
Intestinal Ultrasound for Monitoring Postoperative Crohn’s Disease: A Review and Visual Atlas	11
A NOVEL GUT-RESTRICTED ARYL HYDROCARBON RECEPTOR AGONIST WITH ACTIVITY IN THE DEXTRAN SODIUM SULFATE COLITIS MURINE MODEL	11
Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn’s Disease	11
Characterization of Computed Tomography Colonography Findings of Ulcerative Colitis-Associated Neoplasia	11
Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease Pathogenesis	11
Penetrating ileocolic Crohn disease with intra-abdominal abscess: diagnose, drugs, drain, divert?	11
The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis	11
NAD+ DEPLETION IN THE INTESTINAL EPITHELIUM RESULTS IN MITOCHONDRIAL DYSFUNCTION AND INFLUENCES THE PATHOGENESIS OF EXPERIMENTAL COLITIS	11